Today, Covaxin is set to start with human clinical trails in AIIMS, Delhi after getting the approval from Drugs Controller General of India (DCGI). A total of 375 volunteers are registered for the trial and AIIMS has to select 100 for phase 1 and 2 clinical trials.
ICMR has selected 17 sites to conduct the human trials in India including PGI, Chandigarh and AIIMS Patna.
Covaxin is being developed by Hyderabad based Bharat Biotech in collaboration with Indian Council for Medical Research (ICMR) and National Institute of Virology (NIV)
Besides Covaxin, DCGI has permitted
Reportedly, including Bharat Biotech and Zydus Cadila, a total of 7 pharma companies. AstraZeneca, Serum Institute of India, Panacea Biotec, Indian Immunologicals, Mynvax, Biological E also in India are developing a vaccine for COVID-19 that has already infected more than 14 million globally.
With the coronavirus case tally crossing 11 lakh mark and the new highest single-day spike of 40,425 cases in the last 24 hours, we can now hope for the vaccine to control such pandemic.